Replimune Group, Inc.: Form 10-Q for the period ended Jun 30, 2019
Filed with the SEC on Aug 14, 2019 and accepted by EDGAR at Aug 14, 2019, 16:31 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2019-06-30. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Research and development | 3 months2019-04-01 to 2019-06-30 | $7.5m | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months2019-04-01 to 2019-06-30 | −$10.9m | us-gaap:OperatingIncomeLoss |
| Net income | 3 months2019-04-01 to 2019-06-30 | −$9.5m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2019-04-01 to 2019-06-30 | −$0.30 | us-gaap:EarningsPerShareBasicAndDiluted |
| Operating cash flow | 3 months2019-04-01 to 2019-06-30 | −$13.6m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 3 months2019-04-01 to 2019-06-30 | $362.0k | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | At period end2019-06-30 | $38.4m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2019-06-30 | $127.7m | us-gaap:AssetsCurrent |
| Total assets | At period end2019-06-30 | $143.5m | us-gaap:Assets |
| Current liabilities | At period end2019-06-30 | $13.1m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2019-06-30 | $13.4m | us-gaap:Liabilities |
| Shareholders' equity | At period end2019-06-30 | $130.2m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001104659-19-045938. Last ingested by Listed: Nov 6, 2026, 16:43 ET. Listed shows no prices and gives no investment advice.